We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Sets Endpoint for Trials Testing Lupus Treatments
FDA Sets Endpoint for Trials Testing Lupus Treatments
June 25, 2010
Drugmakers developing products for the treatment of systemic lupus erythematosus (SLE) should use a disease activity index such as the British Isles Lupus Assessment Group as the primary efficacy endpoint in clinical trials, the FDA says.